The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2007, 179, 2097 -2104
Copyright © 2007 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomescu, C.
Right arrow Articles by Montaner, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomescu, C.
Right arrow Articles by Montaner, L. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH

NK Cell Lysis of HIV-1-Infected Autologous CD4 Primary T Cells: Requirement for IFN-Mediated NK Activation by Plasmacytoid Dendritic Cells1

Costin Tomescu*, Jihed Chehimi*, Vernon C. Maino{dagger} and Luis J. Montaner2,*

* HIV Immunopathogenesis Laboratory, Wistar Institute, Philadelphia, PA 19104; and {dagger} BD Biosciences, San Jose, CA 95131


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
In vivo, several mechanisms have been postulated to protect HIV-1-infected cells from NK surveillance. In vitro, previous research indicates HIV-1-infected autologous CD4+ primary T cells are resistant to NK lysis. We hypothesized that NK lysis of HIV-1-infected target cells would be augmented by the presence of accessory cells and/or accessory cell factors. In this study, we show that stimulation of plasmacytoid dendritic cells (PDC) with the TLR9 agonist, CpG ODN 2216, triggered NK lysis of HIV-1-infected autologous CD4+ primary T cells. PDC-stimulated NK lysis was dependent upon MHC class I (MHC-I) down-regulation on infected cells, and primary HIV-1 isolates that exhibited enhanced MHC-I down-regulation were more susceptible to NK-mediated lysis. PDC-stimulated NK lysis of HIV-1-infected autologous CD4+ primary T cells was blocked by neutralizing Abs to type 1 IFN and was perforin/granzyme dependent. Overall, our data suggest that HIV-infected cells are not innately resistant to NK lysis, and that exogenous NK stimulation derived from PDC can trigger NK cytotoxicity against HIV-1-infected autologous CD4+ primary T cells.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Following Ag uptake, dendritic cells use pathogen recognition receptors, such as the TLRs, to identify specific bacterial or viral motifs and trigger activation events such as cytokine release. Plasmacytoid dendritic cells (PDC),3 which comprise the main IFN-{alpha}-producing cells in the circulation, constitutively express TLR7/TLR9 and respond to viral/bacterial genomic material such as ssRNA or CpG oligodeoxynucleotide (ODN) motif-containing dsDNA (1, 2, 3, 4). In vivo, PDC have been directly shown to be a critical cell subset in the immune response against viral infection (5, 6), and both PDC frequency and IFN-{alpha} production have been shown to be retained in HIV-1 long-term nonprogressors (7).

However, studies of innate immune function in chronically infected HIV-1 subjects reveal a dramatically decreased frequency of circulating PDC as well as diminished TLR9 ligand-stimulated IFN-{alpha} secretion by PBMCs during HIV-1 viremia (8, 9, 10, 11, 12). Similarly, CD16+/CD56+/CD3– NK cells, the major circulating NK subset, are also selectively depleted during HIV-1 viremia (13, 14). In vitro, evidence confirms that PBMCs from HIV-1-infected subjects exhibit a significant decrease in NK-dependent cytotoxicity against MHC class I (MHC-I)-devoid K562 target cells and lower cytokine-induced IFN-{gamma} production (15, 16, 17). In vivo, HIV-1 replication also results in the altered expression of inhibitory (increased killer Ig-related receptor (KIR)2DL1/p58.1, KIR2DL2/p58.2, and leucocyte Ig-like receptor/Ig-like transcript 2 (ILT2) and activating (decreased NKp30, NKp44, and NKp46) receptors on NK cells (18, 19), further impairing the cytotoxic potential of the remaining NK pool.

Nevertheless, studies from several groups have shown a degree of reversibility in the decrease in NK cytotoxic function following successful treatment of HIV-1-infected subjects with antiretroviral therapy or through direct stimulation of NK cells in vitro with accessory cell stimuli, such as IFN-{alpha} or IL-12 (16, 20, 21, 22). In vitro, NK-mediated lysis against virus-infected target cells has been shown to require the presence of HLA-DR+ IFN-{alpha}-producing cells (23, 24, 25, 26, 27), and IFN-{alpha} production by PDC is observed following stimulation with HIV-infected CD4+ T cells in vitro (28, 29). Therefore, PDC responses may represent an important component of the host antiviral immune response with direct implications on NK function, yet their ability to stimulate NK lysis of autologous HIV-infected targets remains undetermined.

During viral infection or tumor transformation, when MHC-I proteins are often down-regulated, the lack of NK-inhibitory receptor signaling renders target cells susceptible to NK-mediated lysis. As a result, tumor cell lines lacking MHC-I or expressing heterologous MHC-I proteins have been shown to be highly susceptible to NK lysis (30, 31). In contrast, previous research indicates that autologous CD4+ primary T cells infected with HIV-1 (aHIV+CD4) are resistant to NK lysis unless KIR-expressing NK cells are removed from the NK pool (32, 33). The selective down-regulation of HLA-A and HLA-B by HIV-1 negative factor (34) in conjunction with an up-regulation of HLA-E on HIV-1-infected CD4+ T cells (35, 36) have been postulated to protect HIV-1-infected cells from NK surveillance. We now show that stimulation of NK cells by CpG ODN 2216-activated PDC triggers NK lysis of aHIV+CD4 via a mechanism dependent on type 1 IFN. In infected cells that are lysed by NK, MHC-I down-regulation was a major determinant for PDC-stimulated NK lysis. Overall, our data support a role for functional NK responses in immune surveillance of HIV-1-infected target cells and highlight the potential for PDC activation to trigger NK lysis of aHIV+CD4.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
PBMC purification and cell purification

Blood was drawn from a panel of 50 healthy, HIV-1-seronegative donors from the Wistar Institute Blood Donor Program. Institutional Review Board approval (from the Wistar Institute) and informed consent were obtained before blood donation. PBMC were separated by Ficoll-Paque (Amersham Biosciences) density gradient separation and were cultured at 2.5 x 106/ml in RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 15% FBS and antibiotics. CD4+ primary T cells were isolated from PBMCs by positive selection using anti-CD4 magnetic beads (Miltenyi Biotec), and purified NK cells were isolated from whole blood by negative selection using NK rosette mixture (StemCell Technologies), according to the manufacturer’s instructions. CD4+ T cell and NK cell purity was tested by flow cytometry using Abs to the cell surface markers CD4/CD3 and CD3/CD56/CD16, respectively, and routinely found to be >95%. PDC were enriched to >98% purity from PBMCs using PDC enrichment mixture (Diamond Isolation Kit; Miltenyi Biotec), according to the manufacturer’s instructions. NK-depleted PBMCs (<1.5% NK positive) were prepared using anti-CD56+ magnetic beads in conjunction with LD depletion column (Miltenyi Biotec).

HIV-1 infection

PBMCs were stimulated for 3 days with 10 µg/ml PHA-p (Sigma-Aldrich) and 100 U/ml human IL-2 (BD Pharmingen) before CD4+ primary T cell purification and infected according to the following spinfection protocol: 5 x 106 CD4+ primary T cells were infected with 150 ng of p24 containing HIV-1 supernatant in the presence of 8 µg/ml polybrene (Sigma-Aldrich) for 2 h at 1800 rpm. Uninfected CD4+ primary T cells were exposed to polybrene and spun alongside infected cells. At 4 days postinfection, HIV-1-infected and uninfected CD4+ primary T cells were passed through a CD4-negative selection magnetic column (Miltenyi Biotec) before use in flow cytometric or NK-mediated cytotoxicity assays to remove non-CD4-contaminating cells. Nonviable cells were subsequently removed by Ficoll density gradient separation. The purity and viability of infected and uninfected CD4+ primary T cells were >95% in all reported experiments.

The HIV-1 isolate TYBE (X4 tropic, from CNS) was isolated at the University of Pennsylvania Centers for AIDS Research Viral Core Facility, and the HIV-1 isolates NL4-3 (X4), IIIB (X4), and 96USHIPS9 (R5/X4) were obtained from the National Institutes of Health AIDS Research and Reference Reagent Program (National Institutes of Health). All isolates were expanded and titered by the University of Pennsylvania Centers for AIDS Research Viral Core Facility.

Flow cytometry

All cell surface Abs and isotype controls were used at the recommended dilution of 0.25 µg of Ab/million cells in PBSA (PBS with 0.09% sodium azide). The Abs used in this study include CD3 (SK7), CD4 (SK3), CD16 (3GB), CD56 (B159), CD69 (FN50), CD107a (H4A3), MHC class I A2 (BB7.2), MHC class I A,B,C (G462.6), CD161 (DX12), and NKG2D (ID-11) from BD Pharmingen; NKp30 (Z25), NKp44 (Z231), NKp46 (BAB281), NKG2A (Z199), KIR2DL1/S1 (EB6B), KIR2DL2/3/S2 (GL183), and LIR/ILT2 (HP-F1) from Beckman Coulter; and BDCA-4 (neutropilin-1) (AD5-17F6) from Miltenyi Biotec. Cells were permeabilized for intracellular staining with the Cytofix/Cytoperm kit (BD Pharmingen), as described by the manufacturer. Intracellular p24 staining to identify HIV-1-infected cells was performed with a PE-conjugated mouse mAb against the HIV-1 p24 gag protein (clone KC57; Beckman Coulter) used at a 1/1000 dilution. A minimum of 100,000 events was collected on a FACSCalibur flow cytometer, and samples were subsequently analyzed with FlowJo software (Tree Star). Before analysis, all samples were gated by forward and side scatter to exclude dead cells.

NK cytotoxicity assay

A total of 1 x 106 HIV-1-infected or uninfected CD4 T cells was labeled with 100 µCu of Na251CrO4 for 3 h in complete medium supplemented with 100 U/ml IL-2, washed twice, and cocultured with autologous PBMCs or purified NK cells at various E:T ratios. Percentage cytotoxicity was calculated as described previously (16). The percent specific lysis adjusted for infectivity (%SL/%p24) was calculated by subtracting nonspecific PBMC lysis of uninfected CD4+ primary T cells from HIV-1-specific lysis and adjusting for the percentage of infected (p24-positive) cells within each experiment (see depiction of methodology in Fig. 3A).


Figure 3
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 3. MHC-I down-regulation is associated with susceptibility of HIV-1-infected autologous CD4+ primary T cells to CpG-2216-stimulated PBMC lysis. A, A representative depiction of the method for normalization of a donor’s NK lysis activity based on the subtraction of background lysis against uninfected target cells (specific lysis, on left) and adjustment for the frequency of p24 Ag-positive cells (%SL/%p24, on right). B, %SL/%p24-normalized lysis data from 10 autologous donors tested for both unstimulated and CpG-2216-stimulated PBMC lysis of NL4-3- and SHIP-infected CD4+ T cells at a 100:1 E:T cell ratio. C, Regression analysis of %SL/%p24 vs MHC-I expression following CpG-2216 stimulation of PBMC lysis at a 100:1 E:T cell ratio. The %SL/%p24 results with NL4-3, IIIB, SHIP, and TYBE are included.

 
In the indicated experiments, PBMC or purified PDC were treated for 18 h with 10 µg/ml CpG ODN 2216 (InvivoGen). When enriched PDC were added to purified NK cells for CpG ODN 2216 stimulation experiments, the optimal NK to PDC ratio was determined individually for each donor based upon the ratio of NK to PDC present within PBMCs (typically between 5:1 and 25:1). When indicated, purified NK cells or PBMCs were incubated directly with 1000 U/ml rIFN-{alpha} 2a (Roferon/Roche). In all cases, the supernatant was removed following overnight stimulation and effector cells were washed twice before culturing with autologous labeled target cells. Of note, no change in spontaneous or experimental target cell lysis was observed in the presence of supernatants from 18-h stimulation of effectors with CpG-2216 or IFN-{alpha} 2a. During IFN-blocking experiments, neutralizing sera against human IFN-{alpha}/beta (sheep polyclonal) and anti-human IFN-{alpha}/beta receptor 2 (mouse, monoclonal IgG1) were added 30 min before and during CpG ODN 2216 stimulation of PBMC at 10 µg/ml (R&D Systems). As controls, normal sheep serum and mouse monoclonal IgG1 isotype controls were used at 10 µg/ml. During concanamycin A experiments, CpG ODN 2216-stimulated or unstimulated PBMCs were pretreated for 3 h before and during the chromium lysis assay with 100 ng/ml concanamycin A (Sigma-Aldrich) in DMSO or DMSO alone.

CD107a degranulation assay

PBMC or purified NK cells were cocultured alone (no target control) or with HIV-1-infected or uninfected autologous CD4 primary T cells at a 5:1 E:T ratio in the presence of 5 µg/ml brefeldin A (Sigma-Aldrich) and 20 µl of anti-CD107a mAb for 4 h, as previously described (37). NK cells were gated by CD56+/CD3– staining, and CD107a expression was determined based on background levels of staining exhibited by no target control cells.

IFN-{alpha} ELISA

Supernatants from overnight stimulation of PBMC with CpG ODN 2216 were collected and frozen at –80°C. Supernatants were thawed and tested in duplicate for IFN-{alpha} secretion using the IFN-{alpha} 2a ELISA kit (PBL Biomedical Laboratories), according to the manufacturer’s instructions.

Statistical analysis

Statistical analyses were performed with JMP Software. Wilcoxon matched pair, nonparametric t tests were used for paired analysis. Linear regression analysis was performed with normally distributed and independent data. In all cases, p values were two sided with significance <0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
CpG stimulation of PBMC augments NK-dependent lysis of aHIV+CD4

We hypothesized that NK lysis of aHIV+CD4 would be augmented by the presence of accessory cell and/or accessory cell factors. We began by testing both laboratory-adapted (IIIB, NL4-3) and primary strains (96USHIPS9, TYBE) of HIV-1 to control for viral strain-specific differences in NK susceptibility. As shown in Fig. 1, all four isolates possessed a similar capacity to infect CD4 primary T cells, as determined by intracellular p24 levels (Fig. 1A, insets) and down-regulation of CD4 from the cell surface (data not shown). However, we observed that the primary HIV-1 strains TYBE and 96USHIPS9 (SHIP) exhibited a significantly greater capacity to down-regulate MHC-I when compared with the laboratory-adapted strain IIIB or NL4-3 (Fig. 1B). As a result, we postulated that the increased capacity of SHIP and TYBE to induce MHC-I down-regulation would lead to an enhanced susceptibility of these isolates to NK lysis. Nevertheless, in support of previous findings (33), we observed that aHIV+CD4 were resistant to lysis by either purified NK cells or total PBMCs, regardless of the HIV-1 strain used for infection (Fig. 2, A and B).


Figure 1
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 1. Enhanced down-regulation of MHC-I by primary HIV-1 isolates. A, PHA/IL-2-stimulated CD4+ primary T cells were infected with laboratory-adapted (IIIB or NL4-3) or primary (96USHIPS9 or TYBE) HIV-1 isolates for 4 days, stained with Abs to MHC class I (pan W6/32), and permeabilized for intracellular p24 expression (insets). HIV-1-specific MHC-I down-regulation was determined by gating p24-positive cells and overlaying over mock-uninfected cells (gray, shaded histogram). B, Composite analysis of PHA/IL-2-stimulated CD4+ T cells from multiple donors infected with laboratory-adapted or primary HIV-1 isolates for 4 days and stained for MHC-I down-regulation, as in A.

 

Figure 2
View larger version (26K):
[in this window]
[in a new window]

  		FIGURE 2. CpG stimulation of PBMC triggers lysis of HIV-1-infected autologous CD4+ primary T cells. A, NK cytotoxicity assay of purified NK cells (left) or PBMCs (right) incubated at increasing E:T ratios with autologous CD4+ primary T cells infected with NL4-3 or SHIP. B, NK cytotoxicity assay of unstimulated (left) or CpG-2216-stimulated PBMCs (right) incubated at increasing E:T ratios with autologous CD4+ primary T cells infected with IIIB or TYBE. All results are representative of a minimum of three independent experiments. C, CD107 degranulation was measured on CD56+/CD3–-gated NK cells following PBMC (unstimulated or CpG-2216-stimulated) incubation with HIV-1-infected or uninfected autologous CD4+ primary T cells for 4 h. Results shown are from incubations of effectors with uninfected (left), IIIB-infected (center), and TYBE-infected (right) autologous CD4+ primary T cells. Values represent percentage of CD56+/CD3–-gated NK cells staining positive for CD107 in the presence of targets (black, open histograms) compared with control cultures incubated in the absence of targets (gray, shaded histograms). D, Composite analysis of multiple donors showing CD107 degranulation results in CD56+/CD3–-gated NK cells following PBMC (unstimulated or CpG-2216-stimulated) incubation with autologous CD4+ primary T cells infected with laboratory-adapted or primary HIV-1 isolates. Results are inclusive of infections with IIIB, NL4-3 (laboratory-adapted), or SHIP, TYBE (primary isolate) HIV-1 strains. Values were calculated, as in C.

 
We next tested whether preactivation of dendritic cells could overcome the observed block to NK lysis of aHIV+CD4. As a stimuli, we choose the TLR9 ligand, CpG ODN 2216 (CpG-2216), which can activate PDC to secrete IFN-{alpha} and activate NK (1, 2, 3, 4). As shown in Fig. 2B, we found that pretreatment of PBMC with CpG-2216 triggered a strong HIV-1-specific lysis against TYBE-infected aHIV+CD4. However, lysis of aHIV+CD4 infected with the IIIB isolate, which lacked the ability to down-regulate MHC-I, was similar to uninfected cell background. An increase in background lysis against uninfected CD4 T cells was also noted, although it was substantially lower than lysis against TYBE-infected aHIV+CD4. These results were further supported by CD107a flow-based degranulation assay, which showed that prestimulation of PBMCs with CpG-2216 triggered degranulation of CD56+/CD3–-gated NK cells in response to TYBE-infected aHIV+CD4, but not lab-adapted aHIV+CD4 (Fig. 2, C and D).

In subsequent experiments, we separated the HIV-specific increase in lysis of aHIV+CD4 from background activity against uninfected CD4 primary T cells by subtraction of uninfected cell lysis from HIV-1-specific lysis following CpG-2216 stimulation of PBMCs. We then adjusted for differences in efficiency of HIV-1 infection between experiments by normalizing each experiment by intracellular p24 expression (see Fig. 3A). Using this approach, we found a statistically significant increase in PBMC lysis of SHIP-infected (p < 0.05, n = 10), but not NL4-3-infected aHIV+CD4 following CpG stimulation (Fig. 3B), in support of our previous results with TYBE and IIIB. For all viral isolates tested, MHC-I down-regulation in aHIV+CD4 was found to positively regress with NK lysis following CpG induction of PBMC, confirming the role of MHC-I down-regulation in target cell susceptibility to NK lysis (Fig. 3C).

Next, we confirmed that CpG-dependent PBMC lysis of aHIV+CD4 was mediated through PDC stimulation of NK cells. First, depletion of NK cells from PBMC led to a substantial reduction in CpG-2216-stimulated PBMC lysis of aHIV+CD4, as shown in Fig. 4A. Second, direct incubation of purified NK with PDC in the presence of CpG-2216 triggered NK activation (as evidenced by CD69 up-regulation) and lysis of aHIV+CD4 (Fig. 4, B and C). In contrast, direct stimulation of NK with CpG-2216, or incubation of NK with PDC in the absence of CpG-2216, failed to trigger NK CD69 expression or lysis of aHIV+CD4 (Fig. 4, B and C).


Figure 4
View larger version (32K):
[in this window]
[in a new window]

  		FIGURE 4. CpG-2216-activated PDC trigger NK-dependent lysis of HIV-1-infected autologous CD4+ primary T cells. A, NK cytotoxicity assay of CpG-2216-stimulated PBMCs (left) or NK-depleted CpG-2216-stimulated PBMCs (right) incubated with SHIP-infected autologous CD4+ primary T cells at a 100:1 E:T cell ratio. Lysis is represented as %SL/%p24. B, Dotplot showing the CD69 expression (x-axis) on CD56+ NK cells (y-axis) incubated alone or with autologous PDC for 18 h in the presence or absence of CpG-2216. NK/PDC coculture ratios of 5:1 and 25:1 are shown for the indicated donor. C, NK cytotoxicity assay of isolated NK or NK/PDC cocultures that were stimulated in presence or absence of CpG-2216 for 18 h and incubated with TYBE-infected autologous CD4+ primary T cells at 4:1 E:T ratio. NK/PDC coculture ratios of 5:1 and 25:1 are shown for the indicated donor, and lysis is represented as %SL/%p24. All results are representative of a minimum of three independent experiments.

 
Together these results strongly indicated that NK lysis of aHIV+CD4 was induced by the presence of PDC accessory cell help, and is dependent on the extent of MHC-I down-regulation in infected target cells.

CpG-2216 stimulation of PDC triggers lysis of aHIV+CD4 through type 1 IFN-mediated NK activation and perforin granule exocytosis

In addition to confirming that CpG-2216 stimulation of PBMC triggers the production of IFN-{alpha} (Fig. 5A), we directly tested the role of type 1 IFN in PDC stimulation of NK activity through the use of blocking Abs. As shown in Fig. 5, B and C, we observed a complete reduction in CD69 up-regulation on NK cells as well as a reduction in CpG-2216-stimulated NK lysis of aHIV+CD4 in the presence of neutralizing Abs against IFN-{alpha}/beta and the IFN-{alpha}/beta receptor, IFN-R2. Conversely, the ability to increase both NK and PBMC cytotoxicity through the addition of exogenous IFN-{alpha} 2a alone suggests that secretion of IFN-{alpha} by PDC can stimulate NK lysis of aHIV+CD4 (Fig. 5D).


Figure 5
View larger version (28K):
[in this window]
[in a new window]

  		FIGURE 5. Requirement for type 1 IFN in PDC-stimulated NK lysis of HIV-1-infected autologous CD4+ primary T cells. A, ELISA results measuring secretion of IFN-{alpha} 2a by PBMCs from six donors incubated in the presence or absence of CpG-2216 for 18 h. B, CD69 expression in CD3–/CD56+ NK cells from unstimulated (gray, shaded histograms) and CpG-2216-stimulated (black, open histograms) PBMCs incubated in the presence of neutralizing Abs to IFN-{alpha}/beta, IFN-R2 (right), or the appropriate isotype control Abs (left) for 18 h. C, NK cytotoxicity assay of PBMCs stimulated for 18 h with CpG-2216 in the presence of neutralizing Abs to IFN-{alpha}/beta, IFN-R2, or the appropriate isotype control Abs, followed by incubation with TYBE-infected CD4+ primary T cells at 100:1 E:T ratio. Lysis is represented as %SL/%p24. D, NK cytotoxicity assay of unstimulated or IFN-{alpha} 2a-stimulated purified NK cells (left) or PBMCs (right) incubated with TYBE-infected CD4+ primary T cells at 4:1 E:T ratio and 100:1 E:T ratio, respectively. Lysis is represented as %SL/%p24. All results are representative of a minimum of three independent experiments.

 
To investigate the mechanism through which CpG-2216 stimulation of PDC augments NK lysis of HIV-1-infected targets, we tested the effect of CpG-2216 pretreatment on the expression of NK-inhibitory and activating receptors. As shown in Fig. 6A, stimulation of PBMCs with CpG-2216 did not alter the expression of any of the measured inhibitory or activating receptors on CD56+/CD3–-gated NK cells, including CD16, NKG2D, NKp30, NKp44, NKp46, KIR2DL1/S1, KIR2DL2/3/S2, CD161, NKG2A, and ILT2. However, CpG-2216 stimulation did result in the robust up-regulation of CD69, an activation marker associated with NK activation via IFN-{alpha}, as shown in Fig. 5B. Analysis of CD56+/CD3–-gated NK cells following a 4-h incubation of CpG-2216-stimulated PBMCs with aHIV+CD4 also showed no change in the expression of activating or inhibitory NK receptors on CD107a-degranulated NK cells (data not shown), as has been described following receptor/ligand interaction in other NK/target systems (38, 39, 40).


Figure 6
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 6. CpG-2216 stimulation of PBMC results in NK activation and perforin-dependent lysis of HIV-1-infected autologous CD4+ primary T cells. A, Frequency of CD56+/CD3– NK cells staining positive for CD69, CD16, NKG2D, NKp30, NKp44, NKp46, KIR2DL1/S1, KIR2DL2/3/S2, CD161, NKG2A, or ILT2 following 18-h incubation of PBMC in the presence (dark gray bars) or absence (light gray bars) of CpG-2216. Results represent an average of five independent donors tested. B, Effect of concanamycin A treatment on perforin expression in CD56+ NK cells. The geometric mean perforin expression on NK cells is listed in the upper right quadrant of PBMC following incubation with concanamycin A in DMSO or DMSO alone for 3 h. C, Composite analysis of the number of perforin-expressing CD3–/CD56+ NK cells from four individual donors tested with DMSO or concanamycin A. D, NK cytotoxicity assay of CpG-2216-stimulated PBMCs incubated with NL4-3- or SHIP-infected CD4+ primary T cells at a 100:1 E:T ratio following pretreatment with concanamycin A in DMSO or DMSO alone for 3 h. All results are representative of a minimum of three independent experiments.

 
We next investigated the mechanism of killing used by NK cells in lysing aHIV+CD4 following PDC stimulation using the perforin inhibitor, concanamycin A. As previously reported (41), we observed that pretreatment of purified NK cells (data not shown) or PBMCs (Fig. 6, B and C) with concanamycin A decreased intracellular perforin content in CD56+ NK cells. Indicative of a role of the perforin/grazyme pathway, pretreatment with concanamycin A also led to inhibition of PBMC-mediated lysis of aHIV+CD4 following CpG-2216 stimulation (Fig. 6D). As expected, pretreatment with concanamycin A did not alter CD107a degranulation of CpG-2216-stimulated PBMCs following coculture with aHIV+CD4 (data not shown).

Together, these results establish that CpG-2216 stimulation of PBMCs results in PDC secretion of IFN-{alpha} and activation of NK to lyse aHIV+CD4 in a perforin/granzyme-dependent mechanism without modulation of major inhibitory or activating NK receptors.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In this study, we document the first evidence that NK responses are able to recognize and lyse aHIV+CD4 in the presence of CpG-2216-activated PDC or IFN-{alpha}. Although PDC enhancement of NK lysis has been described against nonautologous virally infected targets or transformed tumor cells, we now establish that viral evasion mechanisms exhibited by HIV-1 to guard against NK lysis do not prevent NK cytotoxicity if PDC stimulation is present. Specifically, we found that CpG-2216 stimulation of PDC led to a significant increase in NK-dependent lysis against aHIV+CD4 when MHC-I was down-regulated following infection (Figs. 2 and 4), and that the stimulatory effect of CpG-2216 was mediated through activation of NK via type 1 IFN (Fig. 5). Our data highlight the ability of the NK cytotoxic response to lyse HIV-1-infected autologous CD4 primary T cell targets in the presence of PDC function. Conversely, in the absence of PDC stimulation, our data support previous reports of an inefficient lysis of aHIV+CD4 by NK cells despite MHC-1 down-regulation (33).

It is of relevance to note that our findings concerning CpG-2216-stimulated PBMC lysis of aHIV+CD4 are most likely an underestimate of the total potential effect due to the inefficiency of HIV-1 infection achieved within CD4+ primary T cells (typically 35–55% infected; see Fig. 1A). By comparison, virally infected heterologous targets such as SupT1 (in which close to 100% of cells are infected) or MHC-devoid cell lines such as K562 cells are highly susceptible to NK lysis. As depicted in Fig. 3A, we addressed this limitation by correcting PBMC lysis by the percentage of p24-positive cells in each experiment and subtracting nonspecific lysis of uninfected cells.

We established a role for PDC and type 1 IFN in mediating CpG-2216-stimulated PBMC lysis of aHIV+CD4 through the addition of activated PDC directly to isolated NK cells (Fig. 4C), as well as by neutralizing type 1 IFN activity by blocking IFN-{alpha}/beta and the IFN-{alpha}/beta receptor, IFN-R2 (Fig. 5C). Taken together with the observations that exogenous IFN-{alpha} can mediate similar anti-HIV activity (Fig. 5D), and recent data identifying stimulated PDC products with anti-HIV activity independent of IFN-{alpha} (42), our data add support to the interpretation that activation of PDC may promote innate antiviral mechanisms of control against HIV-1. Of note, we also observed an increase in the background level of PBMC lysis against uninfected CD4+ primary T cells following CpG-2216 stimulation. We postulate that this increase is due to a lowering of the threshold of NK lysis toward all targets because no change in the major inhibitory or activating receptors on NK cells other than CD69 was noted (Fig. 6A). Importantly, the PDC-stimulated NK lysis of aHIV+CD4 was always greater than the background level of lysis against uninfected CD4+ primary T cells, allowing us to interpret the presence of HIV-1-specific lysis against aHIV+CD4.

Previously, research from several groups has indicated that enriched PDC cultures can respond directly to HIV-1-infected CD4+ primary T cells through TLR7-mediated production of IFN-{alpha} (28, 29). It is of relevance to stress that in our experiments shown in this study, a maximum of 4-h incubation was present between unstimulated PBMC and aHIV+CD4, which may not be long enough to allow for PDC recognition of infected target cells and NK-dependent lysis. It remains to be determined whether TLR7-mediated IFN-{alpha} from prolonged incubations with aHIV+CD4 can result in NK-mediated lysis, as suggested by our data.

In terms of a mechanism for CpG-2216-stimulated NK cytotoxic function, previous research has shown that HIV-1 gp41 can induce the expression of a NKp44 ligand on CD4+ primary T cells and sensitize infected targets to lysis by IL-2-activated NK cells in vitro (43, 44). However, we found that NKp44 was not expressed by NK cells in our system either before or following CpG-2216 stimulation of PBMCs (Fig. 6A), suggesting that alternative mechanisms of NK recognition may be responsible for the observed lysis of autologous HIV-1-infected targets following PDC stimulation. In terms of NK-inhibitory receptors, previous research has shown that the removal of NK cells expressing inhibitory KIR augments NK lysis of aHIV+CD4 (32). Our results showing a significant correlation between the degree of MHC-I down-regulation on aHIV+CD4 and the extent of PDC-stimulated NK lysis (Fig. 3C) further suggest a dominant role for MHC-I/KIR interactions in regulating NK lysis of autologous targets.

In vivo, the correlation between PDC/NK responses, IFN-{alpha}, and HIV-1 control is supported by several important observations, as follows: 1) long-term nonprogressors have retained PDC and NK function in the presence of low viral loads (7); 2) PDC frequency has been implicated as a correlate of viral rebound following therapy interruption (12, 45); 3) increased NK activity has been proposed as a correlate of protection in HIV-1-exposed, but uninfected Vietnamese i.v. drug users (46); 4) exogenous IFN-{alpha} has been shown to result in a drop of >0.5 log in viral load in vivo when introduced in the absence of antiretroviral therapy (47); and 5) the NK-activating receptor allele, KIR3DS1, in combination with HLA-B Bw4, is associated with delayed progression to AIDS in individuals infected with HIV-1 (48). Based on our observations supporting the ability of NK to lyse HIV-infected autologous targets following PDC accessory cell stimulation, it remains to be investigated whether NK cytotoxic activity contributes to mechanisms of HIV-1 control in vivo. It is also of interest that despite PDC dysfunction in chronic HIV-1 infection (8, 9, 10, 11, 12), a positive correlation between IFN-{alpha} serum levels and disease progression has been described (11). It remains to be determined what biological activity circulating IFN-{alpha} has in activating NK cytotoxicity when compared with de novo production by PDC following in vitro stimulation with CpG-2216.

Activation of MHC-I-dependent mechanisms of NK lysis upon acute infection or upon anti-retroviral therapy-mediated immune reconstitution may represent powerful correlates of vaccine protection and viral control, respectively, when in the presence of functional NK and PDC compartments. The cooperative role between NK cells and PDC in control of HIV-1 supports further consideration of this mechanism of antiviral activity in advancement of immune-based therapies targeting functional activation/reconstitution of NK or PDC compartments during HIV-1 infection.


   Acknowledgments
 
We thank Dr. Farida Shaheen (supervisor, Centers for AIDS Research Viral Core Facility, University of Pennsylvania, Philadelphia, PA) for the expansion and titering of all HIV-1 strains used in our studies. We also thank Deborah Davis for her contribution as phlebotomist and coordinator of the Wistar Blood Donor Program for our studies.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by grants from the National Institutes of Health (AI51225, AI47760, U01AI065279, AI07632, and AI068405), the Philadelphia Foundation, and funds from the Commonwealth Universal Research Enhancement Program, Pennsylvania Department of Health. Back

2 Address correspondence and reprint requests to Dr. Luis J. Montaner, HIV Immunopathogenesis Laboratory, Wistar Institute, 3601 Spruce Street, Room 480, Philadelphia, PA 19104. E-mail address: Montaner{at}wistar.org Back

3 Abbreviations used in this paper: PDC, plasmacytoid dendritic cell; aHIV+CD4, autologous CD4+ primary T cells infected with HIV-1; ILT2, Ig-like transcript 2; KIR, killer Ig-related receptor; ODN, oligodeoxynucleotide. Back

Received for publication December 19, 2006. Accepted for publication June 1, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Vollmer, J., R. Weeratna, P. Payette, M. Jurk, C. Schetter, M. Laucht, T. Wader, S. Tluk, M. Liu, H. L. Davis, A. M. Krieg. 2004. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34: 251-262. [Medline]
  2. Kerkmann, M., S. Rothenfusser, V. Hornung, A. Towarowski, M. Wagner, A. Sarris, T. Giese, S. Endres, G. Hartmann. 2003. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170: 4465-4474. [Abstract/Free Full Text]
  3. Fitzgerald-Bocarsly, P.. 2002. Natural interferon-{alpha} producing cells: the plasmacytoid dendritic cells. BioTechniques (Suppl.) 33: 16-29.
  4. Krug, A., S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, Z. K. Ballas, S. Endres, A. M. Krieg, G. Hartmann. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-{alpha}/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31: 2154-2163. [Medline]
  5. Smit, J. J., B. D. Rudd, N. W. Lukacs. 2006. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J. Exp. Med. 203: 1153-1159. [Abstract/Free Full Text]
  6. Yoneyama, H., K. Matsuno, E. Toda, T. Nishiwaki, N. Matsuo, A. Nakano, S. Narumi, B. Lu, C. Gerard, S. Ishikawa, K. Matsushima. 2005. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J. Exp. Med. 202: 425-435. [Abstract/Free Full Text]
  7. Almeida, M., M. Cordero, J. Almeida, A. Orfao. 2005. Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS 19: 261-271. [Medline]
  8. Chehimi, J., D. E. Campbell, L. Azzoni, D. Bacheller, E. Papasavvas, G. Jerandi, K. Mounzer, J. Kostman, G. Trinchieri, L. J. Montaner. 2002. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J. Immunol. 168: 4796-4801. [Abstract/Free Full Text]
  9. Feldman, S., D. Stein, S. Amrute, T. Denny, Z. Garcia, P. Kloser, Y. Sun, N. Megjugorac, P. Fitzgerald-Bocarsly. 2001. Decreased interferon-{alpha} production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin. Immunol. 101: 201-210. [Medline]
  10. Donaghy, H., A. Pozniak, B. Gazzard, N. Qazi, J. Gilmour, F. Gotch, S. Patterson. 2001. Loss of blood CD11c+ myeloid and CD11c– plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98: 2574-2576. [Abstract/Free Full Text]
  11. Soumelis, V., I. Scott, F. Gheyas, D. Bouhour, G. Cozon, L. Cotte, L. Huang, J. A. Levy, Y. J. Liu. 2001. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 98: 906-912. [Abstract/Free Full Text]
  12. Pacanowski, J., L. Develioglu, I. Kamga, M. Sinet, M. Desvarieux, P. M. Girard, A. Hosmalin. 2004. Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection. J. Infect. Dis. 190: 1889-1892. [Medline]
  13. Hu, P. F., L. E. Hultin, P. Hultin, M. A. Hausner, K. Hirji, A. Jewett, B. Bonavida, R. Detels, J. V. Giorgi. 1995. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56– cells with low lytic activity. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10: 331-340. [Medline]
  14. Lucia, B., C. Jennings, R. Cauda, L. Ortona, A. L. Landay. 1995. Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. Cytometry 22: 10-15. [Medline]
  15. Sirianni, M. C., I. Mezzaroma, F. Aiuti, A. Moretta. 1994. Analysis of the cytolytic activity mediated by natural killer cells from acquired immunodeficiency syndrome patients in response to phytohemagglutinin or anti-CD16 monoclonal antibody. Eur. J. Immunol. 24: 1874-1878. [Medline]
  16. Azzoni, L., E. Papasavvas, J. Chehimi, J. R. Kostman, K. Mounzer, J. Ondercin, B. Perussia, L. J. Montaner. 2002. Sustained impairment of IFN-{gamma} secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J. Immunol. 168: 5764-5770. [Abstract/Free Full Text]
  17. Ullum, H., P. C. Gotzsche, J. Victor, E. Dickmeiss, P. Skinhoj, B. K. Pedersen. 1995. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. J. Exp. Med. 182: 789-799. [Abstract/Free Full Text]
  18. Mavilio, D., J. Benjamin, M. Daucher, G. Lombardo, S. Kottilil, M. A. Planta, E. Marcenaro, C. Bottino, L. Moretta, A. Moretta, A. S. Fauci. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. USA 100: 15011-15016. [Abstract/Free Full Text]
  19. De Maria, A., M. Fogli, P. Costa, G. Murdaca, F. Puppo, D. Mavilio, A. Moretta, L. Moretta. 2003. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur. J. Immunol. 33: 2410-2418. [Medline]
  20. Huang, X. L., Z. Fan, T. Murayama, C. Rinaldo. 1995. Enhancement of natural killer cell activity in human immunodeficiency virus-infected subjects by in vitro treatment with biologic response modifier OK-432. Clin. Diagn. Lab. Immunol. 2: 91-97. [Medline]
  21. Portales, P., J. Reynes, V. Pinet, R. Rouzier-Panis, V. Baillat, J. Clot, P. Corbeau. 2003. Interferon-{alpha} restores HIV-induced alteration of natural killer cell perforin expression in vivo. AIDS 17: 495-504. [Medline]
  22. Chehimi, J., G. Trinchieri. 1994. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J. Clin. Immunol. 14: 149-161. [Medline]
  23. Feldman, M., D. Howell, P. Fitzgerald-Bocarsly. 1992. Interferon-{alpha}-dependent and -independent participation of accessory cells in natural killer cell-mediated lysis of HSV-1-infected fibroblasts. J. Leukocyte Biol. 52: 473-482. [Abstract]
  24. Fitzgerald-Bocarsly, P., M. Feldman, S. Curl, J. Schnell, T. Denny. 1989. Positively selected Leu-11a (CD16+) cells require the presence of accessory cells or factors for the lysis of herpes simplex virus-infected fibroblasts but not herpes simplex virus-infected Raji. J. Immunol. 143: 1318-1326. [Abstract]
  25. Bandyopadhyay, S., B. Perussia, G. Trinchieri, D. S. Miller, S. E. Starr. 1986. Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts. J. Exp. Med. 164: 180-195. [Abstract/Free Full Text]
  26. Oh, S. H., S. Bandyopadhyay, D. S. Miller, S. E. Starr. 1987. Cooperation between CD16(Leu-11b)+ NK cells and HLA-DR+ cells in natural killing of herpesvirus-infected fibroblasts. J. Immunol. 139: 2799-2802. [Abstract]
  27. Perussia, B., V. Fanning, G. Trinchieri. 1985. A leukocyte subset bearing HLA-DR antigens is responsible for in vitro {alpha} interferon production in response to viruses. Nat. Immun. Cell Growth Regul. 4: 120-137. [Medline]
  28. Schmidt, B., B. M. Ashlock, H. Foster, S. H. Fujimura, J. A. Levy. 2005. HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology 343: 256-266. [Medline]
  29. Yonezawa, A., R. Morita, A. Takaori-Kondo, N. Kadowaki, T. Kitawaki, T. Hori, T. Uchiyama. 2003. Natural {alpha} interferon-producing cells respond to human immunodeficiency virus type 1 with {alpha} interferon production and maturation into dendritic cells. J. Virol. 77: 3777-3784. [Abstract/Free Full Text]
  30. Jaattela, M.. 1990. Effects of heat shock on cytolysis mediated by NK cells, LAK cells, activated monocytes and TNFs {alpha} and beta. Scand. J. Immunol. 31: 175-182. [Medline]
  31. Warren, H. S., A. L. Jones, C. Freeman, J. Bettadapura, C. R. Parish. 2005. Evidence that the cellular ligand for the human NK cell activation receptor NKp30 is not a heparan sulfate glycosaminoglycan. J. Immunol. 175: 207-212. [Abstract/Free Full Text]
  32. Bonaparte, M. I., E. Barker. 2004. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 104: 2087-2094. [Abstract/Free Full Text]
  33. Bonaparte, M. I., E. Barker. 2003. Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS 17: 487-494. [Medline]
  34. Cohen, G. B., R. T. Gandhi, D. M. Davis, O. Mandelboim, B. K. Chen, J. L. Strominger, D. Baltimore. 1999. The selective down-regulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10: 661-671. [Medline]
  35. Nattermann, J., H. D. Nischalke, V. Hofmeister, B. Kupfer, G. Ahlenstiel, G. Feldmann, J. Rockstroh, E. H. Weiss, T. Sauerbruch, U. Spengler. 2005. HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir. Ther. 10: 95-107. [Medline]
  36. Martini, F., C. Agrati, G. D’Offizi, F. Poccia. 2005. HLA-E up-regulation induced by HIV infection may directly contribute to CD94-mediated impairment of NK cells. Int. J. Immunopathol. Pharmacol. 18: 269-276. [Medline]
  37. Alter, G., J. M. Malenfant, M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294: 15-22. [Medline]
  38. Huard, B., L. Karlsson, F. Triebel. 2001. KIR down-regulation on NK cells is associated with down-regulation of activating receptors and NK cell inactivation. Eur. J. Immunol. 31: 1728-1735. [Medline]
  39. Groh, V., J. Wu, C. Yee, T. Spies. 2002. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738. [Medline]
  40. Song, H., J. Kim, D. Cosman, I. Choi. 2006. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell. Immunol. 239: 22-30. [Medline]
  41. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156: 3678-3686. [Abstract]
  42. Groot, F., T. M. van Capel, M. L. Kapsenberg, B. Berkhout, E. C. de Jong. 2006. Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood 108: 1957-1964. [Abstract/Free Full Text]
  43. Vieillard, V., J. L. Strominger, P. Debre. 2005. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc. Natl. Acad. Sci. USA 102: 10981-10986. [Abstract/Free Full Text]
  44. Vieillard, V., D. Costagliola, A. Simon, P. Debre. 2006. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection. AIDS 20: 1795-1804. [Medline]
  45. Kamga, I., S. Kahi, L. Develioglu, M. Lichtner, C. Maranon, C. Deveau, L. Meyer, C. Goujard, P. Lebon, M. Sinet, A. Hosmalin. 2005. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J. Infect. Dis. 192: 303-310. [Medline]
  46. Scott-Algara, D., L. X. Truong, P. Versmisse, A. David, T. T. Luong, N. V. Nguyen, I. Theodorou, F. Barre-Sinoussi, G. Pancino. 2003. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171: 5663-5667. [Abstract/Free Full Text]
  47. Hatzakis, A., P. Gargalianos, V. Kiosses, M. Lazanas, V. Sypsa, C. Anastassopoulou, V. Vigklis, H. Sambatakou, C. Botsi, D. Paraskevis, C. Stalgis. 2001. Low-dose IFN-{alpha} monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. J. Interferon Cytokine Res. 21: 861-869. [Medline]
  48. Martin, M. P., X. Gao, J. H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, et al 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31: 429-434. [Medline]



This article has been cited by other articles:


Home page
 J. Virol.Home page
S. J. Conry, K. A. Milkovich, N. L. Yonkers, B. Rodriguez, H. B. Bernstein, R. Asaad, F. P. Heinzel, M. Tary-Lehmann, M. M. Lederman, and D. D. Anthony
Impaired Plasmacytoid Dendritic Cell (PDC)-NK Cell Activity in Viremic Human Immunodeficiency Virus Infection Attributable to Impairments in both PDC and NK Cell Function
J. Virol., November 1, 2009; 83(21): 11175 - 11187.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
C. Tomescu, J. Chehimi, V. C. Maino, and L. J. Montaner
Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-{alpha} by human NK cells after CD107a degranulation
J. Leukoc. Biol., May 1, 2009; 85(5): 871 - 876.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomescu, C.
Right arrow Articles by Montaner, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomescu, C.
Right arrow Articles by Montaner, L. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS